Why the study?
Guideline-recommended CVD prediction models differ in populations, predictors, and outcome definitions, leaving the implications for risk estimation unclear and direct comparisons limited.
How do the guideline-endorsed PREVENT, SCORE2, and QRISK3 cardiovascular disease risk prediction models compare in discrimination, calibration, and transportability across sex and outcome definitions in an external validation cohort?
Cohort (n=502,157)
Yes
How do the guideline-endorsed PREVENT, SCORE2, and QRISK3 cardiovascular disease risk prediction models compare in discrimination, calibration, and transportability across sex and outcome definitions in an external validation cohort?
Answers are grounded in this paper and cite their sources.
Despite substantial differences in predictors and outcome definitions, PREVENT, SCORE2, and QRISK3 achieve comparable discrimination in the UK Biobank—performing better in females than males—but systematically overestimate 10-year CVD risk, suggesting a need for regional recalibration.
Background Cardiovascular disease (CVD) prediction models recommended by guidelines are developed using different populations, predictors, and outcome definitions. The implications of this heterogeneity for risk estimation are unclear, and direct comparisons remain limited.Objectives Head-to-head comparison of the performance and transportability of three guideline-endorsed CVD risk prediction models, focusing on their sex-specific performance. Methods We evaluated models recommended by the American Heart Association (PREVENT), European Society of Cardiology (SCORE2), and the National Institute for Health and Care Excellence (QRISK3). Risk of bias was assessed using the PROBAST tool. External validation was performed using the UK Biobank (UKBB) in a primary analysis including all participants with complete data for all models, enabling direct comparison, and in a secondary analysis applying each model to participants meeting its original eligibility criteria. Model performance was assessed using Brier scores, Area Under the Receiver Operating Characteristic Curve (AUC), and calibration across original and alternative outcome definitions, stratified by sex. Results The PREVENT, SCORE2, and QRISK3 models varied substantially in terms of predictors, populations, and outcome definitions. We used data from 502,157 UKBB participants for the external validation in the primary analysis. Overall predictive performance (discrimination & calibration), as measured by Brier scores, was generally better in females. The AUC (95% CI) ranged from 0.7092 (0.7090-0.7094) to 0.7468 (0.7465-0.7471) for female and 0.6813 (0.6812-0.6814) to 0.6946 (0.6945-0.6946) for male populations. Calibration was suboptimal, particularly for older individuals, with systematic overestimation of risk. The models showed consistent performance when applied to different outcomes. All models were at high risk of bias. Conclusion Despite heterogeneity in populations, predictors, and outcome definitions, PREVENT, SCORE2, and QRISK3 showed similar performance in the UKBB. Future studies should focus on prospective and standardized definitions and assessment of candidate predictors and outcomes.
No takes yet. Share an insight, caveat, or question.
Kastrati et al. (2026) conducted a cohort in Cardiovascular disease risk prediction in the general population (n=502,157). Guideline-recommended CVD risk prediction models (PREVENT, SCORE2, QRISK3) vs. Head-to-head comparison across models and alternative CVD outcome definitions was evaluated on 10-year cardiovascular disease risk prediction performance (discrimination via AUC and overall accuracy/calibration via Brier score, slope, and intercept).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: